Lmcg Investments LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Lmcg Investments LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 16.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,691 shares of the company’s stock after selling 12,853 shares during the quarter. Lmcg Investments LLC’s holdings in Johnson & Johnson were worth $9,601,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Christopher J. Hasenberg Inc purchased a new position in Johnson & Johnson during the first quarter worth $31,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson during the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $46,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on JNJ shares. TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $167.02 on Tuesday. The stock has a market capitalization of $401.96 billion, a PE ratio of 10.41, a PEG ratio of 2.71 and a beta of 0.53. The company has a 50 day moving average price of $159.98 and a 200-day moving average price of $153.98. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 2.97%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.